Lake Street Downgrades Streamline Health Solutions (STRM) to Hold
Get Alerts STRM Hot Sheet
Rating Summary:
3 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 14 | New: 26
Join SI Premium – FREE
Lake Street Capital Markets downgraded Streamline Health Solutions (NASDAQ: STRM) from Buy to Hold with a price target of $4.00 (from $6.00). The change follows Q1 results. Analyst Bruce D. Jackson said the stock is "essentially dead money until the management team shows they can deliver the goods."
"Streamline Health reported disappointing FQ1 revenue that was below expectations as the turnaround once again failed to materialize during the quarter," said Jackson.
"We are not taking up our forward F2015 revenue estimates to offset FQ1, which brings our annual revenue estimate to $28.4 million. We are also lowering our price target to $4 from $6 based on the company’s inability to execute on its guidance. The new price target is based on a 2.5x multiple to the NTM revenue estimate, which is consistent with the comp group averages. The stock could regain its previous 3x-4x multiple if the company can manage to string together a few quarters of consistent revenue growth. Investors can afford to wait one more quarter for verification that the commercial operations plan is working before getting more constructive on the stock," added the analyst.
For an analyst ratings summary and ratings history on Streamline Health Solutions click here. For more ratings news on Streamline Health Solutions click here.
Shares of Streamline Health Solutions closed at $2.46 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Deutsche Bank Downgrades L'Oreal SA (OR:FP) (LRLCY) to Sell
- Southwest (LUV) PT Raised to $61 at UBS Ahead of Q2 Print
- Cytokinetics (CYTK) PT Raised to $118 at Mizuho
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share